Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
January’s Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| March Rank | February Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 2 | AstraZeneca | 49,311 | 2,936 | 62 |
| 2 | 1 | Pfizer | 28,660 | 2,171 | 176 |
| 3 | 3 | Johnson & Johnson | 9,324 | 1,048 | 190 |
| 4 | 4 | GSK | 879 | 270 | 76 |
| 5 | 13 | Lilly | 640 | 235 | 91 |
| 6 | 6 | Merck & Co | 635 | 485 | 201 |
| 7 | 8 | Novartis | 630 | 464 | 14 |
| 8 | 7 | Roche | 562 | 179 | 56 |
| 9 | 5 | Sanofi | 521 | 164 | 52 |
| 10 | 10 | Abbott | 428 | 402 | 21 |
| 11 | 12 | Novo Nordisk | 426 | 257 | 51 |
| 12 | 9 | Bayer | 350 | 155 | 26 |
| 13 | 14 | Gilead | 345 | 149 | 34 |
| 14 | 18 | BMS | 268 | 191 | 8 |
| 15 | 16 | Otsuka | 174 | 9 | 4 |
| 16 | 20 | Takeda | 171 | 144 | 44 |
| 17 | 19 | Regeneron | 170 | 38 | 6 |
| 18 | 23 | Boehringer Ingelheim | 150 | 126 | 36 |
| 19 | 22 | Fresenius | 130 | 98 | 31 |
| 20 | 34 | Servier | 122 | 13 | 0 |
| 21 | 17 | Amgen | 117 | 74 | 29 |
| 22 | 15 | AbbVie | 109 | 86 | 20 |
| 23 | 21 | UCB | 79 | 72 | 51 |
| 24 | 11 | Mylan | 73 | 5 | 0 |
| 25 | 25 | Biogen | 70 | 39 | 2 |
| 26 | 29 | Chugai | 67 | 1 | 1 |
| 27 | 33 | Daiichi Sankyo | 66 | 10 | 3 |
| 28 | 31 | CSL | 51 | 45 | 11 |
| 29 | 28 | Astellas | 50 | 29 | 12 |
| 30 | 26 | Teva | 49 | 45 | 19 |
| 31 | 24 | Merck KGaA | 46 | 36 | 9 |
| 32 | 39 | Allergan | 44 | 6 | 2 |
| 33 | 27 | Menarini | 36 | 30 | 23 |
| 34 | 37 | Eisai | 31 | 18 | 5 |
| 35 | 30 | Ipsen | 25 | 15 | 8 |
| 36 | 36 | Bausch | 20 | 7 | 1 |
| 37 | 38 | Alexion | 18 | 15 | 3 |
| 38 | 32 | Grifols | 12 | 0 | 0 |
| 39 | 35 | Vertex | 10 | 9 | 0 |
| 40 | 40 | Sun | 3 | 0 | 0 |
| 41 | 41 | Aurobindo | 1 | 0 | 0 |
| 42 | 50 | Mitsubishi Tanabe Pharma | 1 | 0 | 0 |
| 50 | 50 | Endo | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Sumitomo Dainippon | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
January’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by healthcare professionals (HCPs) on Twitter during January 2021 remained the same as last month, with one ranking difference with Sanofi overtaking GSK: Pfizer, AstraZeneca, Johnson and Johnson (J&J), Sanofi and GSK.
Whilst Pfizer and AstraZeneca remained at the top of HCPs’ conversations with continued discussion of their COVID-19 vaccines, J&J’s latest press release with new vaccine data stirred HCP discussions online.
The volume of posts from HCPs about top 50 pharma companies decreased by 5% from December, yet was still more than 69,000 posts throughout January. Posts about AstraZeneca increased by 58% and those about J&J more than doubled with a 161% increase.
A lot of people ask me which vaccine they should take, whether it's Pfizer, Astra Zeneca or others.
My answer is simple and always the same.
Take the first one you are offered#VaccinesWork
— Neil Stone (@DrNeilStone) January 17, 2021
The JNJ vaccine results indicate we miraculously have at least 3 safe, highly effective vaccines.
Headlines focus on the 66% overall efficacy. But the big deal is that the single-dose vax was 100% effective against severe disease after day 49, and 85% effective by day 28.
— Atul Gawande (@Atul_Gawande) January 29, 2021
The most shared links by HCPs, from a variety of sources, gave important updates about the key vaccines, including J&J’s latest efficacy data:
- Johnson & Johnson’s press release stating their COVID-19 vaccine candidate had met its primary endpoint was the most shared link by HCPs: 475 times.
- HCPs also shared
an article from the BBC reporting that the gap between Pfizer vaccine doses should have halved.
- A report in The Jerusalem Post was the third most shared, explaining that only 0.04% of Israelis caught COVID-19 after two shots of Pfizer vaccine.
The COVID-19 conversation in the context of top 50 pharma also began to decrease (-11% from December to January), making up 74% of the overall HCP conversation in January.
Outside of the COVID-19 conversation, HCPs used social media to discuss treatment for a variety of diseases. Oncology advancements, including product approvals, were shared online. One example was from Christine Lovly, a US medical oncologist who shared Roche’s FDA decision for tiragolumab in non-small cell lung cancer (NSCLC).
Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer https://t.co/xppMzPKwSB via @YahooNews
— Christine Lovly (@christine_lovly) January 5, 2021
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In January 2021, CREATION Pinpoint® identified 69,504 healthcare professional (HCP) authored tweets from 22,566 individual HCPs mentioning a top-50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between January 1st and January 31st 2021.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In January, 1,531 of these posts mentioned Janssen.
